Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 30, 2026
Procter & Gamble (PG) Delivers Mixed Q4 Results as Shares Decline 3-4%

Procter & Gamble (PG) Delivers Mixed Q4 Results as Shares Decline 3-4%

Key Takeaways

  • Revenue fell short of expectations: Q4 FY2026 net sales reached $21.2 billion, up 2% year-over-year but missing the consensus estimate of approximately $21.38 billion.
  • Core EPS narrowly beat estimates: Adjusted core earnings per share (EPS) came in at $1.43, edging past the analyst consensus of $1.42, though declining 3% from $1.48 in the prior-year quarter.
  • Organic sales were flat: Organic sales growth — a key metric that strips out currency fluctuations, acquisitions, and divestitures — registered 0%, with volume, pricing, and mix all neutral in the quarter.
  • Margins under pressure: Core operating margin contracted 130 basis points year-over-year, marking the third consecutive quarter of margin compression, driven by higher SG&A (selling, general and administrative) costs and commodity inflation.
  • FY2027 guidance disappointed: Management issued fiscal 2027 core EPS guidance of $6.89 to $7.11, with a midpoint of $7.00, slightly below consensus, while projecting total sales growth of just 1% to 3%.
  • Shares declined sharply: PG stock fell approximately 3% to 4% in intraday trading following the release, reflecting investor concern over the soft revenue print and cautious forward outlook.

Earnings Context and Why It Matters

Procter & Gamble’s fourth-quarter fiscal 2026 results, reported on July 29, 2026, provide a useful window into the consumer staples sector during a period of ongoing macroeconomic pressure. As one of the largest consumer packaged goods companies—with well-known brands such as Tide, Pampers, Gillette, and Crest—PG serves as a useful indicator of household spending and broader consumer trends. This report is particularly relevant given persistent inflation, elevated commodity costs partly linked to geopolitical tensions, and more price-sensitive consumers who are shifting toward value options in some categories. With full-year organic sales growth slowing to 1% (down from 2% in FY2025 and 4% in FY2024), investors are watching closely to see whether PG can restore volume growth while maintaining profitability.

Reported Results

For the fourth quarter of fiscal 2026 ended June 30, 2026, Procter & Gamble reported net sales of $21.2 billion, a 2% increase from $20.9 billion in the prior-year period. The top line nonetheless came in below the analyst consensus of approximately $21.38 billion. Foreign exchange added about one percentage point to growth, while volume, pricing, and mix were neutral overall, leaving organic sales flat year-over-year.

GAAP diluted net EPS declined 15% to $1.26, affected by lower gross margins and higher SG&A expenses. Core EPS, which excludes certain one-time items, fell 3% to $1.43 but still edged past the consensus of $1.42. On a currency-neutral basis, core EPS declined 5% from the prior year. Net earnings totaled $3.04 billion, down 16% from $3.62 billion a year earlier.

Segment results were mixed. Beauty delivered 4% organic sales growth, supported by mid-single-digit gains in hair care and skin and personal care. Grooming and Fabric & Home Care were flat organically, Health Care declined 1%, and Baby, Feminine & Family Care posted a 2% organic sales drop as both volume and pricing weakened. I also checked this using Tickeron’s AI Screener to see how PG stacks up against peers in the sector.

For the full fiscal year 2026, PG reported net sales of $87.0 billion (up 3%) and core EPS of $6.89 (up 1%). Operating cash flow reached $19.6 billion, and the company returned more than $15 billion to shareholders through $10.2 billion in dividends and $5.0 billion in share repurchases. The April 2026 dividend increase marked the 70th consecutive year of dividend growth.

Market Reaction and Investor Sentiment

Investors reacted negatively to the results, with PG shares declining roughly 3% to 4% in Wednesday trading. Although the small core EPS beat provided a modest positive, the revenue miss and cautious fiscal 2027 outlook weighed more heavily on sentiment. Management highlighted roughly $1 billion in after-tax headwinds from higher raw material, energy, and transportation costs, partly tied to Middle East developments and oil prices near $90 per barrel. With organic sales stalled and three of five segments showing flat or negative growth, the market focused on the durability of top-line momentum and margin resilience. From what I see, the reaction underscores that investors are prioritizing sustained revenue growth over a one-penny EPS beat in the current environment.

Forward Outlook and Key Factors to Monitor

Looking ahead to fiscal 2027, Procter & Gamble expects organic sales growth of 1% to 3% and core EPS between $6.89 and $7.11, implying flat to 3% growth versus fiscal 2026. Management noted that the first quarter is likely to be the most difficult, with EPS expected to decline at least 5% year-over-year before conditions improve later in the year.

Key variables include the path of commodity costs, especially crude oil, which affects raw materials, energy, and transportation. The company is budgeting for approximately $1 billion in after-tax commodity headwinds, or about $0.56 per share—an 8% drag on core EPS growth. Consumer behavior will also matter, particularly as lower-income households continue to seek value and private-label options. The Beauty segment has held up well, but softness in Grooming, Health Care, and Family Care deserves attention.

Productivity efforts remain central. PG achieved 340 basis points of productivity savings in fiscal 2026 and plans to fund reinvestments through further efficiency gains. E-commerce, which grew 6% and now accounts for 20% of sales, is another area of focus. I’m watching this closely as digital channels continue to evolve. Investors should track quarterly organic sales trends, segment volume performance, and margin trends throughout the year.

Using Tickeron’s AI Tools in My Research

When evaluating earnings reports like this one, I find it helpful to run quick comparisons with Tickeron’s AI Screener. The tool lets me filter stocks by industry, market cap, technical signals, and other criteria to see how PG and similar names are performing relative to peers. It saves time and surfaces ideas I might otherwise miss during earnings season.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PG

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


PG in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 01, 2026

PG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 41 cases where PG's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

PG moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PG crossed bullishly above the 50-day moving average on September 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +1.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where PG advanced for three days, in 153 of 350 cases, the price rose further within the following month. The odds of a continued upward trend are 44%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PG as a result. In 44 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 49%.

The Moving Average Convergence Divergence Histogram (MACD) for PG turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 21 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 44%.

The 50-day moving average for PG moved below the 200-day moving average on September 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.489) is normal, around the industry mean (18.044). P/E Ratio (22.512) is within average values for comparable stocks, (43.673). PG's Projected Growth (PEG Ratio) (3.813) is slightly higher than the industry average of (1.518). Dividend Yield (0.029) settles around the average of (0.024) among similar stocks. P/S Ratio (4.092) is also within normal values, averaging (1.931).

The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. PG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

Notable companies

The most notable companies in this group are Procter & Gamble Company (NYSE:PG), Colgate-Palmolive Company (NYSE:CL).

Industry description

Household/Personal Care companies sell products for home cleaning and/or personal hygiene and grooming purposes. Products of this industry include detergents, shampoos, soaps, cosmetics, fabric conditioners and infant care fragrances. Procter & Gamble, Unilever, Estee Lauder and Colgate-Palmolive are some of the biggest names in the business. A lot of the products become a necessary part of people’s daily routine, and therefore the industry is relatively less vulnerable to macroeconomic downturns. At the same time, product quality, consumer safety, and ease of use are extremely critical factors for a company to survive competition and earn recognition in this industry.

Market Cap

The average market capitalization across the Household/Personal Care Industry is 23.45B. The market cap for tickers in the group ranges from 60.48K to 346.15B. PG holds the highest valuation in this group at 346.15B. The lowest valued company is EOSS at 60.48K.

High and low price notable news

The average weekly price growth across all stocks in the Household/Personal Care Industry was -2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 7%. ODD experienced the highest price growth at 11%, while TANH experienced the biggest fall at -19%.

Volume

The average weekly volume growth across all stocks in the Household/Personal Care Industry was -3%. For the same stocks of the Industry, the average monthly volume growth was -17% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 43
Price Growth Rating: 57
SMR Rating: 72
Profit Risk Rating: 90
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
PG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of branded consumer packaged goods

Industry HouseholdPersonalCare

Industry
Household Or Personal Care
Address
One Procter and Gamble Plaza
Phone
+1 513 983-1100
Employees
104000
Web
https://us.pg.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.